Evaluation of Cardiovascular Risk Among the Participants of the ESC Congress 2026

计划入组 1,300 人 · 首次发布于 2026 年 8 月 21 日

Evaluation of Cardiovascular Risks Among the Participants of the EAPC Congress 2026

计划入组 511 人 · 首次发布于 2026 年 5 月 22 日

Evaluation of Cardiovascular Risks Among the Participants of the ESC Congress 2025

计划入组 1,366 人 · 首次发布于 2026 年 5 月 29 日

US-APR2020

BSIgG (JHSPH/US DoD/NMRC)

Repurposed Eflornithine (Norgine/US WorldMeds)

US HELPING US, PEOPLE INTO LIVING, INC.

United States

Fontem US LLC

United States

US Biotest, Inc.

United States

Promising Pathway Act 2.0 Aims to Expedite Rare Disease Drug Approvals

Swiss Pharma Faces Potential US Section 301 Trade Investigation Over Drug Pricing Policies

FDA Grants First-Ever Waiver of Clinical Efficacy Studies for Monoclonal Antibody Biosimilars